Table of Contents
ISRN Pediatrics
Volume 2014 (2014), Article ID 734689, 8 pages
http://dx.doi.org/10.1155/2014/734689
Research Article

Identification and Prevention of Antiepileptic Drug Noncompliance: The Collaborative Use of State-Supplied Pharmaceutical Data

1Baylor College of Medicine and Texas Children’s Hospital, 6701 Fannin Street No. 1250, Houston, TX 77030, USA
2University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
3Texas Children’s Health Plan, 2450 Holcombe Boulevard, Suite 34L, Houston, TX 77021, USA
4Texas Children’s Health Plan, Baylor College of Medicine, 2450 Holcombe Boulevard, Suite 34L, Houston, TX 77021, USA

Received 9 October 2013; Accepted 14 November 2013; Published 19 February 2014

Academic Editors: M. Adhikari and G. J. Casimir

Copyright © 2014 Joseph C. Hodges et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Friedman and G. Q. Sharieff, “Seizures in children,” Pediatric Clinics of North America, vol. 53, no. 2, pp. 257–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Shinnar and J. M. Pellock, “Update on the epidemiology and prognosis of pediatric epilepsy,” Journal of Child Neurology, vol. 17, supplement 1, pp. S4–S17, 2002. View at Google Scholar · View at Scopus
  3. C. G. Goetz and E. J. Pappert, Textbook of Clinical Neurology, Saunders, Philadelphia, Pa, USA, 2nd edition, 2003.
  4. C. A. Van Donselaar, H. Stroink, and W.-F. Arts, “How confident are we of the diagnosis of epilepsy?” Epilepsia, vol. 47, s1, pp. 9–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Buck, A. Jacoby, G. A. Baker, and D. W. Chadwick, “Factors influencing compliance with antiepileptic drug regimes,” Seizure, vol. 6, no. 2, pp. 87–93, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Loiseau and C. Marchal, “Determinants of compliance in epileptic patients,” Epilepsy Research. Supplement, vol. 1, pp. 135–140, 1988. View at Google Scholar · View at Scopus
  7. E. Santiago-Rodríguez, V. Sales-Carmona, and R. Ramos-Ramírez, “Risk factors for therapeutic non-compliance in patients with epilepsies,” Gaceta Medica de Mexico, vol. 138, no. 3, pp. 241–246, 2002. View at Google Scholar · View at Scopus
  8. S. S. R. Snodgrass, V. V. Vedanarayanan, C. C. Parker, and B. R. Parks, “Pediatric patients with undetectable anticonvulsant blood levels: comparison with compliant patients,” Journal of Child Neurology, vol. 16, no. 3, pp. 164–168, 2001. View at Google Scholar · View at Scopus
  9. I. Lusic, M. Titlic, and D. Eterovic, “Epileptic patient compliance with prescribed medical treatment,” Acta Medica Croatica, vol. 59, pp. 13–18, 2005. View at Google Scholar
  10. M. R. Sperling, H. Feldman, J. Kinman, J. D. Liporace, and M. J. O'Connor, “Seizure control and mortality in epilepsy,” Annals of Neurology, vol. 46, pp. 45–50, 1999. View at Google Scholar
  11. G. M. Peterson, S. McLean, and K. S. Millingen, “Determinants of patient compliance with anticonvulsant therapy,” Epilepsia, vol. 23, no. 6, pp. 607–613, 1982. View at Google Scholar · View at Scopus
  12. J. Wilby, A. Kainth, N. Hawkins et al., “Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation,” Health Technology Assessment, vol. 9, no. 15, 2005. View at Google Scholar · View at Scopus
  13. S. Nadkarni, J. LaJoie, and O. Devinsky, “Current treatments of epilepsy,” Neurology, vol. 64, no. 12, supplement 3, pp. S2–S11, 2005. View at Google Scholar · View at Scopus
  14. P. Camfield and C. Camfield, “Epileptic syndromes in childhood: clinical features, outcomes, and treatment,” Epilepsia, vol. 43, supplement 3, pp. 27–32, 2002. View at Google Scholar · View at Scopus
  15. J. A. French, A. M. Kanner, J. Bautista et al., “Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society,” Neurology, vol. 62, no. 8, pp. 1252–1260, 2004. View at Google Scholar · View at Scopus
  16. J. A. French, A. M. Kanner, J. Bautista et al., “Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society,” Neurology, vol. 62, no. 8, pp. 1261–1273, 2004. View at Google Scholar · View at Scopus
  17. S. M. Hadjiloizou and B. F. D. Bourgeois, “Antiepileptic drug treatment in children,” Expert Review of Neurotherapeutics, vol. 7, no. 2, pp. 179–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Goodwin, D. Wade, B. Luke, and P. Davies, “A survey of a novel epilepsy clinic,” Seizure, vol. 11, no. 8, pp. 519–522, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. E. D. Marsh, A. R. Brooks-Kayal, and B. E. Porter, “Seizures and antiepileptic drugs: does exposure alter normal brain development?” Epilepsia, vol. 47, no. 12, pp. 1999–2010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Polsky, J. Weiner, J. F. Bale Jr., S. Ashwal, and M. J. Painter, “Specialty care by child neurologists: a workforce analysis,” Neurology, vol. 64, no. 6, pp. 942–948, 2005. View at Google Scholar · View at Scopus
  21. F. Buchthal and O. Svensmark, “Aspects of the pharmacology of phenytoin (dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy,” Epilepsia, vol. 1, pp. 373–384, 1960. View at Google Scholar · View at Scopus
  22. F. Buchthal, O. Svensmark, and P. J. Schiller, “Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin,” Archives of Neurology, vol. 2, pp. 624–630, 1960. View at Google Scholar · View at Scopus
  23. W. Froscher, G. Kramer, D. Schmidt, and H. Stefan, “Serum concentration of anticonvulsants: practical guidelines for measuring and useful interpretation. Therapy Committee of the German Section of the International Epilepsy League,” Nervenarzt, vol. 70, pp. 172–177, 1999. View at Google Scholar
  24. W. Froscher, “Clinical relevance of the determination of antiepileptic drugs in serum,” Wiener Klinische Wochenschrift, Supplement, vol. 104, no. 191, pp. 15–18, 1992. View at Google Scholar · View at Scopus
  25. G. E. Schumacher and J. T. Barr, “Total Testing Process applied to therapeutic drug monitoring: impact on patients' outcomes and economics,” Clinical Chemistry, vol. 44, no. 2, pp. 370–374, 1998. View at Google Scholar · View at Scopus
  26. S. R. Snodgrass and B. R. Parks, “Anticonvulsant blood levels: historical review with a pediatric focus,” Journal of Child Neurology, vol. 15, no. 11, pp. 734–746, 2000. View at Google Scholar · View at Scopus
  27. C. F. Nhachi and G. M. Mwaluko, “Therapeutic drug monitoring (TDM): an aid to anti-epileptic drug (AED) therapy in Zimbabwe: a review,” East African Medical Journal, vol. 67, no. 5, pp. 311–318, 1990. View at Google Scholar · View at Scopus
  28. R. J. L. Walters, A. D. Hutchings, D. F. Smith, and P. E. M. Smith, “Inappropriate requests for serum anti-epileptic drug levels in hospital practice,” Monthly Journal of the Association of Physicians, vol. 97, no. 6, pp. 337–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. R. G. Feldman and C. E. Pippenger, “The relation of anticonvulsant drug levels to complete seizure control,” Journal of Clinical Pharmacology, vol. 16, no. 1, pp. 51–59, 1976. View at Google Scholar · View at Scopus
  30. M. Da Mota Gomes, H. De Souza Maia Filho, and R. A. M. Noé, “Anti-epileptic drug intake adherence: the value of the blood drug level measurement and the clinical approach,” Arquivos de Neuro-Psiquiatria, vol. 56, no. 4, pp. 708–713, 1998. View at Google Scholar · View at Scopus
  31. Scottish Intercollegiate Guidelines Network no. 70, “Diagnosis and management of epilepsy in adults,” 2007, http://www.sign.ac.uk/pdf/sign70.pdf.
  32. R. M. Werner and D. Polsky, “Comparing the supply of pediatric subspecialists and child neurologists,” Journal of Pediatrics, vol. 146, no. 1, pp. 20–25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Weinstock, “Chronic Care: an acute problem,” Hospitals & Health Networks, vol. 78, pp. 40–42, 44–48, 2004. View at Google Scholar
  34. P. Rudd, “In search of the gold standard for compliance measurement,” Archives of Internal Medicine, vol. 139, no. 6, pp. 627–628, 1979. View at Publisher · View at Google Scholar · View at Scopus
  35. J. F. Steiner, T. D. Koepsell, S. D. Fihn, and T. S. Inui, “A general method of compliance assessment using centralized pharmacy records. Description and validation,” Medical Care, vol. 26, no. 8, pp. 814–823, 1988. View at Google Scholar · View at Scopus
  36. R. Sikka, F. Xia, and R. E. Aubert, “Estimating medication persistency using administrative claims data,” American Journal of Managed Care, vol. 11, no. 7, pp. 449–457, 2005. View at Google Scholar · View at Scopus
  37. C. L. Bryson, D. H. Au, B. Young, M. B. McDonell, and S. D. Fihn, “A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp),” Medical Care, vol. 45, no. 6, pp. 497–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. A. Hamilton and L. L. Briceland, “Use of prescription-refill records to assess patient compliance,” American Journal of Hospital Pharmacy, vol. 49, no. 7, pp. 1691–1696, 1992. View at Google Scholar · View at Scopus
  39. C. A. W. Rijcken, H. Tobi, A. C. M. Vergouwen, and L. T. W. de Jong-van den Berg, “Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data,” Pharmacoepidemiology and Drug Safety, vol. 13, no. 6, pp. 365–370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. J. F. Steiner and A. V. Prochazka, “The assessment of refill compliance using pharmacy records: methods, validity, and applications,” Journal of Clinical Epidemiology, vol. 50, no. 1, pp. 105–116, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. L. M. Hess, M. A. Raebel, D. A. Conner, and D. C. Malone, “Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures,” Annals of Pharmacotherapy, vol. 40, no. 7-8, pp. 1280–1288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. L. N. Ranganathan and S. Ramaratnam, “Rapid versus slow withdrawal of antiepileptic drugs,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD005003, 2006. View at Google Scholar · View at Scopus
  43. R. S. Greenwood and M. B. Tennison, “When to start and stop anticonvulsant therapy in children,” Archives of Neurology, vol. 56, no. 9, pp. 1073–1077, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Thorbecke, “Patients with epilepsy who discontinue treatment,” Epilepsy Research. Supplement, vol. 1, pp. 119–124, 1988. View at Google Scholar · View at Scopus
  45. L. M. Specchio and E. Beghi, “Should antiepileptic drugs be withdrawn in seizure-free patients?” CNS Drugs, vol. 18, no. 4, pp. 201–212, 2004. View at Publisher · View at Google Scholar · View at Scopus